Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) participated in The American Society of Human Genetics (ASHG) conference from October 14–18, 2025 in Boston. The event highlighted the potential for an expanding role of optical genome mapping (OGM) in genetic disease research. Multiple presentations and posters showcased its effectiveness in detecting structural variants (SVs) associated with a range of genetic conditions, including facioscapulohumeral muscular dystrophy (FSHD), prenatal, and postnatal disorders.

Key Highlights from ASHG 2025:

A total of nine studies, presented as either oral sessions or posters, demonstrated the effectiveness of OGM in detecting novel SVs that can be missed by traditional cytogenetic and sequencing techniques. These findings highlight the significant value OGM can have in addressing complex genetic conditions.

• Completely Resolved Structural Variants by OGM with adaptive sampling from CNV discovery. Li Fu, Yokohama City University Graduate School of Medicine, Japan
  
  
• Optical Genome Mapping and Other Techniques Resolve a Duchenne Muscular Dystrophy Sample. Ulrich Broeckel, Medical College of Wisconsin, USA
  
  
• Improved Algorithms for Optical Genome Mapping Workflows in Constitutional Disease and Oncology Applications. Andy Wing Chun Pang, Bionano, USA
  
  
• Project Baby Magnolia: Implementing OGM at the University of Mississippi Medical Center. Douglas McLaurin, University of Mississippi Medical Center, USA
  
  
• Comparison of Optical Genome Mapping, Chromosomal Microarray and Next-Generation Sequencing for Detection of Structural Variants in Rare Diseases. Kumiko Yanagi, National Center for Child Health and Development, Japan
  
  
• OGM Elucidates Complex Rearrangements Associated with Developmental Delay. Masanori Fujimoto, Nagoya City University Graduate School of Medical Sciences, Japan
  
  
• Leveraging Advanced Genomics in Rare Diseases: Outcomes from the University of Wisconsin Disease Program. Bryn Webb, University of Wisconsin School of Medicine and Public Health, USA
  
  
• Prospective Comparative Evaluation of Optical Genome Mapping, Mate-Pair Genome Sequencing, and Chromosomal Microarray Analysis in Prenatal Disorders. Matthew Hoi Kin Chau, The Chinese University of Hong, China
  
  
• Efficient Detection And Characterization of FSHD1 with Optical Genome Mapping. Trilochan Sahoo, Bionano Laboratories, USA
  
  

The scientific program for the event is available at the ASHG website linked here:

“We’re excited by the growing recognition of optical genome mapping as a transformative tool in genetic research. The studies presented at ASHG 2025 demonstrate OGM’s unique ability to help researchers worldwide gain deeper insights into complex genetic conditions. We remain committed to advancing the OGM technique and supporting the scientific community in uncovering discoveries that can make a meaningful difference in the field of genomics,” commented Erik Holmlin, PhD, president and CEO of Bionano.

For more information on Bionano’s OGM solutions, visit .

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit or .

Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “ability,” “can,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies, among other things, and in this release include, but are not limited to, statements the ability of OGM to have an expanding role in genetic disease research; the ability of OGM to detect novel SVs missed traditional cytogenetic and sequencing techniques; the value of OGM in addressing complex genetic conditions; and ability of OGM to help researchers worldwide gain deeper insights into complex genetic conditions. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM to have an expanding role in genetic disease research; the failure of OGM to detect novel SVs missed traditional cytogenetic and sequencing techniques; the failure of OGM to provide value in addressing complex genetic conditions; the failure of OGM to help researchers worldwide gain deeper insights into complex genetic conditions; the failure of OGM be useful in the applications described in the publications referenced in this press release; future publications that differ or contradict the findings of the publication referenced in this press release; our ability to obtain sufficient financing to fund our business plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our business plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and in the Middle East and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties including those described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

CONTACTS

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

Investor Relations:

Kelly Gura

Gilmartin Group

+1 (212) 229-6163